Combinations that come up in the research literature, and why researchers pair them. Open each component for its own dosing guidance.
Both compounds appear separately in soft-tissue and wound-repair models: BPC-157 mostly in tendon, ligament and gut studies in rodents, and thymosin beta-4 (the parent of TB-500) in angiogenesis and cell-migration work. Researchers pair them to study whether different repair pathways add together. Published head-to-head studies of the combination are scarce, so each figure below comes from single-compound work.
View blend →Components: CJC-1295 + Ipamorelin
Pairs a GHRH analog with a selective ghrelin-receptor agonist. The two act on separate receptors on the same pituitary cells, which makes the pair a model for studying synergy in growth-hormone release.
View blend →Components: GHK-Cu + BPC-157 + TB-500
Combines a copper peptide studied in skin and extracellular-matrix models with two peptides studied in tissue repair. It's used to study skin and connective-tissue remodeling.
View blend →Components: KPV + GHK-Cu + BPC-157 + TB-500
Adds the anti-inflammatory tripeptide KPV to the GLOW set, for inflammation-and-repair research models.
View blend →Components: Cagrilintide + Semaglutide
Pairs an amylin analog with a GLP-1 receptor agonist. The combination (CagriSema) has been tested in published clinical trials of appetite and body-weight regulation.
View blend →Components: Melanotan II + PT-141
Both are melanocortin-receptor agonists; PT-141 (bremelanotide) is a metabolite of Melanotan II. They are compared in studies of melanocortin receptor pharmacology.